GERON CORP
Geron Corporation (NASDAQ: GRON) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for blood cancers. The company's flagship product, RYTELO (imetelstat), is a first-in-class telomerase inhibitor that received FDA approval in June 2024 for treating adult patients with… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What GERON CORP does
In the company’s own words
Geron Corporation (NASDAQ: GRON) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for blood cancers. The company's flagship product, RYTELO (imetelstat), is a first-in-class telomerase inhibitor that received FDA approval in June 2024 for treating adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. RYTELO also received European Commission approval in March 2025, making it the first and only telomerase inhibitor approved in the European Union. The company launched RYTELO commercially in the United States in June 2024 and is pursuing commercialization strategies in select European markets through partnerships with experienced third parties.
Geron's pipeline includes the Phase 3 IMpactMF clinical trial evaluating imetelstat in patients with relapsed or refractory myelofibrosis, which completed enrollment in September 2025. The company is also conducting investigator-led studies in higher-risk myelodysplastic syndromes, acute myeloid leukemia, and frontline myelofibrosis, as well as pursuing a discovery program for next-generation oral telomerase inhibitors.
The company's technology is based on telomerase inhibition, targeting the enzyme that enables malignant cells to proliferate indefinitely. Imetelstat is designed to bind to telomerase's RNA template, thereby suppressing proliferation of malignant stem and progenitor cells while minimizing effects on normal cells. This approach is grounded in Nobel Prize-winning science related to telomere biology.
Geron maintains global commercial rights to RYTELO and holds issued patents providing coverage through 2033 in the United States and Europe, with potential for patent term extensions. The company operates with a commercial infrastructure including over 60 key account managers and regional teams supporting patient access through its REACH4RYTELO patient support program. The company's website is www.geron.com. Geron operates as a Delaware corporation with wholly owned subsidiaries in the United Kingdom and Netherlands.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- FOSTER CITY, CA
- Fiscal year end
- December
- CIK
- 886744
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns GERON CORP — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · GERON CORP’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do GERON CORP and its peers compare on margins and cash generation over ten years?”
- “Where did five years of GERON CORP's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in GERON CORP's last four quarterly filings that the numbers alone won't show?”